25 XP   0   0   10

Taxus Cardium Pharmaceuticals Group Inc
Buy, Hold or Sell?

Let's analyse Taxus Cardium Pharmaceuticals Group Inc together

PenkeI guess you are interested in Taxus Cardium Pharmaceuticals Group Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Taxus Cardium Pharmaceuticals Group Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Taxus Cardium Pharmaceuticals Group Inc

I send you an email if I find something interesting about Taxus Cardium Pharmaceuticals Group Inc.

Quick analysis of Taxus Cardium Pharmaceuticals Group Inc (30 sec.)










What can you expect buying and holding a share of Taxus Cardium Pharmaceuticals Group Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
10.0%

What is your share worth?

Current worth
$-0.07
Expected worth in 1 year
$-0.05
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
$0.02
Return On Investment
17,344.9%

For what price can you sell your share?

Current Price per Share
$0.00
Expected price per share
$0.0001 - $0.0001
How sure are you?
50%

1. Valuation of Taxus Cardium Pharmaceuticals Group Inc (5 min.)




Live pricePrice per Share (EOD)

$0.00

Intrinsic Value Per Share

$-0.40 - $0.39

Total Value Per Share

$-0.47 - $0.32

2. Growth of Taxus Cardium Pharmaceuticals Group Inc (5 min.)




Is Taxus Cardium Pharmaceuticals Group Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$4.5m-$4.8m$281.5k6.2%

How much money is Taxus Cardium Pharmaceuticals Group Inc making?

Current yearPrevious yearGrowGrow %
Making money-$575.2k$866.6k-$1.4m-250.6%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Taxus Cardium Pharmaceuticals Group Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

What can you expect buying and holding a share of Taxus Cardium Pharmaceuticals Group Inc? (5 min.)

Welcome investor! Taxus Cardium Pharmaceuticals Group Inc's management wants to use your money to grow the business. In return you get a share of Taxus Cardium Pharmaceuticals Group Inc.

What can you expect buying and holding a share of Taxus Cardium Pharmaceuticals Group Inc?

First you should know what it really means to hold a share of Taxus Cardium Pharmaceuticals Group Inc. And how you can make/lose money.

Speculation

The Price per Share of Taxus Cardium Pharmaceuticals Group Inc is $0.0001. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Taxus Cardium Pharmaceuticals Group Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Taxus Cardium Pharmaceuticals Group Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.07. Based on the TTM, the Book Value Change Per Share is $0.00 per quarter. Based on the YOY, the Book Value Change Per Share is $0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Taxus Cardium Pharmaceuticals Group Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.01-8,860.0%-0.01-8,860.0%0.0113,347.4%0.00-3,606.8%-0.05-49,815.8%
Usd Book Value Change Per Share0.004,336.2%0.004,336.2%0.000.0%0.00-2,383.6%-0.02-16,406.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.002,411.4%0.001,205.7%
Usd Total Gains Per Share0.004,336.2%0.004,336.2%0.000.0%0.0027.8%-0.02-15,200.9%
Usd Price Per Share0.00-0.00-0.04-0.07-0.21-
Price to Earnings Ratio-0.01--0.01-2.85-1.12--1.14-
Price-to-Total Gains Ratio0.02-0.02-4.76-4.80-
Price to Book Ratio0.00-0.00--0.51--1.11-2.68-
Price-to-Total Gains Ratio0.02-0.02-4.76-4.80-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0001
Number of shares10000000
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (10000000 shares)43,362.20277.64
Gains per Year (10000000 shares)173,448.801,110.58
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1017344917343996455-953451101
20346898346888192911-1906902212
30520346520337289366-2860343323
40693795693786385822-3813794434
50867244867235482277-4767245545
6010406931040684578732-5720696656
7012141421214133675188-6674147767
8013875901387582771643-7627598878
9015610391561031868099-8581039989
10017344881734480964554-95344811100

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%2.01.00.066.7%2.03.00.040.0%2.08.00.020.0%2.023.00.08.0%
Book Value Change Per Share1.00.00.0100.0%2.00.01.066.7%3.01.01.060.0%4.04.02.040.0%11.011.03.044.0%
Dividend per Share0.00.01.00.0%0.00.03.00.0%1.00.04.020.0%1.00.09.010.0%2.00.023.08.0%
Total Gains per Share1.00.00.0100.0%2.00.01.066.7%3.01.01.060.0%4.04.02.040.0%11.011.03.044.0%

Fundamentals of Taxus Cardium Pharmaceuticals Group Inc

About Taxus Cardium Pharmaceuticals Group Inc

Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.

Fundamental data was last updated by Penke on 2024-05-15 22:23:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Taxus Cardium Pharmaceuticals Group Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Taxus Cardium Pharmaceuticals Group Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Taxus Cardium Pharmaceuticals Group Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Taxus Cardium Pharmaceuticals Group Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-922.3%+922.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--171.8%+171.8%
TTM--211.9%+211.9%
YOY--263.3%+263.3%
5Y--414.0%+414.0%
10Y-922.3%-552.3%-370.0%
1.1.2. Return on Assets

Shows how efficient Taxus Cardium Pharmaceuticals Group Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Taxus Cardium Pharmaceuticals Group Inc to the Biotechnology industry mean.
  • -101.5% Return on Assets means that Taxus Cardium Pharmaceuticals Group Inc generated $-1.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Taxus Cardium Pharmaceuticals Group Inc:

  • The MRQ is -101.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -101.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-101.5%TTM-101.5%0.0%
TTM-101.5%YOY2,445.8%-2,547.3%
TTM-101.5%5Y851.8%-953.2%
5Y851.8%10Y-1,673.0%+2,524.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-101.5%-11.9%-89.6%
TTM-101.5%-11.5%-90.0%
YOY2,445.8%-10.9%+2,456.7%
5Y851.8%-13.1%+864.9%
10Y-1,673.0%-14.4%-1,658.6%
1.1.3. Return on Equity

Shows how efficient Taxus Cardium Pharmaceuticals Group Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Taxus Cardium Pharmaceuticals Group Inc to the Biotechnology industry mean.
  • 0.0% Return on Equity means Taxus Cardium Pharmaceuticals Group Inc generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Taxus Cardium Pharmaceuticals Group Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-88.3%+88.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--15.3%+15.3%
TTM--14.6%+14.6%
YOY--13.6%+13.6%
5Y--17.7%+17.7%
10Y-88.3%-19.2%-69.1%

1.2. Operating Efficiency of Taxus Cardium Pharmaceuticals Group Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Taxus Cardium Pharmaceuticals Group Inc is operating .

  • Measures how much profit Taxus Cardium Pharmaceuticals Group Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Taxus Cardium Pharmaceuticals Group Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Taxus Cardium Pharmaceuticals Group Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-739.2%+739.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--336.0%+336.0%
TTM--224.0%+224.0%
YOY--280.1%+280.1%
5Y--412.2%+412.2%
10Y-739.2%-521.7%-217.5%
1.2.2. Operating Ratio

Measures how efficient Taxus Cardium Pharmaceuticals Group Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Taxus Cardium Pharmaceuticals Group Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y7.593-7.593
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.005-3.005
TTM-3.247-3.247
YOY-3.619-3.619
5Y-5.262-5.262
10Y7.5936.874+0.719

1.3. Liquidity of Taxus Cardium Pharmaceuticals Group Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Taxus Cardium Pharmaceuticals Group Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.08 means the company has $0.08 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Taxus Cardium Pharmaceuticals Group Inc:

  • The MRQ is 0.082. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.082. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.082TTM0.0820.000
TTM0.082YOY0.007+0.075
TTM0.0825Y0.065+0.016
5Y0.06510Y0.390-0.325
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0823.805-3.723
TTM0.0824.158-4.076
YOY0.0075.252-5.245
5Y0.0656.087-6.022
10Y0.3906.434-6.044
1.3.2. Quick Ratio

Measures if Taxus Cardium Pharmaceuticals Group Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Taxus Cardium Pharmaceuticals Group Inc to the Biotechnology industry mean.
  • A Quick Ratio of 0.08 means the company can pay off $0.08 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Taxus Cardium Pharmaceuticals Group Inc:

  • The MRQ is 0.077. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.077. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.077TTM0.0770.000
TTM0.077YOY0.000+0.077
TTM0.0775Y0.061+0.016
5Y0.06110Y0.236-0.176
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0773.202-3.125
TTM0.0773.816-3.739
YOY0.0005.183-5.183
5Y0.0615.929-5.868
10Y0.2366.351-6.115

1.4. Solvency of Taxus Cardium Pharmaceuticals Group Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Taxus Cardium Pharmaceuticals Group Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Taxus Cardium Pharmaceuticals Group Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 9.06 means that Taxus Cardium Pharmaceuticals Group Inc assets are financed with 905.7% credit (debt) and the remaining percentage (100% - 905.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Taxus Cardium Pharmaceuticals Group Inc:

  • The MRQ is 9.057. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 9.057. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ9.057TTM9.0570.000
TTM9.057YOY137.864-128.807
TTM9.0575Y64.903-55.846
5Y64.90310Y53.396+11.507
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.0570.344+8.713
TTM9.0570.342+8.715
YOY137.8640.279+137.585
5Y64.9030.366+64.537
10Y53.3960.380+53.016
1.4.2. Debt to Equity Ratio

Measures if Taxus Cardium Pharmaceuticals Group Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Taxus Cardium Pharmaceuticals Group Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Taxus Cardium Pharmaceuticals Group Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y0.158-0.158
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.398-0.398
TTM-0.415-0.415
YOY-0.353-0.353
5Y-0.446-0.446
10Y0.1580.470-0.312

2. Market Valuation of Taxus Cardium Pharmaceuticals Group Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Taxus Cardium Pharmaceuticals Group Inc generates.

  • Above 15 is considered overpriced but always compare Taxus Cardium Pharmaceuticals Group Inc to the Biotechnology industry mean.
  • A PE ratio of -0.01 means the investor is paying $-0.01 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Taxus Cardium Pharmaceuticals Group Inc:

  • The EOD is -0.011. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.011. Based on the earnings, the company is expensive. -2
  • The TTM is -0.011. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.011MRQ-0.0110.000
MRQ-0.011TTM-0.0110.000
TTM-0.011YOY2.847-2.858
TTM-0.0115Y1.122-1.133
5Y1.12210Y-1.137+2.259
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.011-2.313+2.302
MRQ-0.011-2.535+2.524
TTM-0.011-2.723+2.712
YOY2.847-3.958+6.805
5Y1.122-6.316+7.438
10Y-1.137-6.544+5.407
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Taxus Cardium Pharmaceuticals Group Inc:

  • The EOD is -0.006. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.006. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.006. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.006MRQ-0.0060.000
MRQ-0.006TTM-0.0060.000
TTM-0.006YOY-17.989+17.983
TTM-0.0065Y-23.182+23.176
5Y-23.18210Y-15.772-7.410
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.006-3.099+3.093
MRQ-0.006-3.270+3.264
TTM-0.006-3.523+3.517
YOY-17.989-5.220-12.769
5Y-23.182-8.080-15.102
10Y-15.772-8.637-7.135
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Taxus Cardium Pharmaceuticals Group Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.00 means the investor is paying $0.00 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Taxus Cardium Pharmaceuticals Group Inc:

  • The EOD is -0.001. Based on the equity, the company is expensive. -2
  • The MRQ is -0.001. Based on the equity, the company is expensive. -2
  • The TTM is -0.001. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.001MRQ-0.0010.000
MRQ-0.001TTM-0.0010.000
TTM-0.001YOY-0.509+0.507
TTM-0.0015Y-1.111+1.109
5Y-1.11110Y2.677-3.788
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.0012.009-2.010
MRQ-0.0012.029-2.030
TTM-0.0012.065-2.066
YOY-0.5092.688-3.197
5Y-1.1113.688-4.799
10Y2.6774.095-1.418
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Taxus Cardium Pharmaceuticals Group Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0040.0040%-+100%-0.002+155%-0.016+478%
Book Value Per Share---0.070-0.0700%-0.075+6%-0.071+2%-0.038-45%
Current Ratio--0.0820.0820%0.007+1086%0.065+25%0.390-79%
Debt To Asset Ratio--9.0579.0570%137.864-93%64.903-86%53.396-83%
Debt To Equity Ratio----0%-0%-0%0.158-100%
Dividend Per Share----0%-0%0.002-100%0.001-100%
Eps---0.009-0.0090%0.013-166%-0.004-59%-0.050+462%
Free Cash Flow Per Share---0.018-0.0180%-0.002-88%-0.012-29%-0.037+112%
Free Cash Flow To Equity Per Share--0.0060.0060%-0.001+121%0.002+275%-0.007+226%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--0.390--------
Intrinsic Value_10Y_min---0.403--------
Intrinsic Value_1Y_max--0.003--------
Intrinsic Value_1Y_min---0.038--------
Intrinsic Value_3Y_max--0.036--------
Intrinsic Value_3Y_min---0.118--------
Intrinsic Value_5Y_max--0.103--------
Intrinsic Value_5Y_min---0.199--------
Market Cap6493.1900%6493.1906493.1900%2467412.200-100%4862100.672-100%13335713.622-100%
Net Profit Margin----0%-0%-0%-9.2230%
Operating Margin----0%-0%-0%-7.3920%
Operating Ratio----0%-0%-0%7.593-100%
Pb Ratio-0.0010%-0.001-0.0010%-0.509+35694%-1.111+78030%2.677-100%
Pe Ratio-0.0110%-0.011-0.0110%2.847-100%1.122-101%-1.137+9975%
Price Per Share0.0000%0.0000.0000%0.038-100%0.075-100%0.205-100%
Price To Free Cash Flow Ratio-0.0060%-0.006-0.0060%-17.989+314744%-23.182+405625%-15.772+275940%
Price To Total Gains Ratio0.0230%0.0230.0230%--4.765-100%4.804-100%
Quick Ratio--0.0770.0770%0.000+91333%0.061+27%0.236-67%
Return On Assets---1.015-1.0150%24.458-104%8.518-112%-16.730+1549%
Return On Equity----0%-0%-0%-0.8830%
Total Gains Per Share--0.0040.0040%-+100%0.000+15518%-0.015+451%
Usd Book Value---4568204.000-4568204.0000%-4849763.000+6%-4637258.000+2%-2490598.000-45%
Usd Book Value Change Per Share--0.0040.0040%-+100%-0.002+155%-0.016+478%
Usd Book Value Per Share---0.070-0.0700%-0.075+6%-0.071+2%-0.038-45%
Usd Dividend Per Share----0%-0%0.002-100%0.001-100%
Usd Eps---0.009-0.0090%0.013-166%-0.004-59%-0.050+462%
Usd Free Cash Flow---1136438.000-1136438.0000%-137162.000-88%-811520.000-29%-2407415.800+112%
Usd Free Cash Flow Per Share---0.018-0.0180%-0.002-88%-0.012-29%-0.037+112%
Usd Free Cash Flow To Equity Per Share--0.0060.0060%-0.001+121%0.002+275%-0.007+226%
Usd Market Cap6493.1900%6493.1906493.1900%2467412.200-100%4862100.672-100%13335713.622-100%
Usd Price Per Share0.0000%0.0000.0000%0.038-100%0.075-100%0.205-100%
Usd Profit---575297.000-575297.0000%866675.000-166%-439011.200-24%-3233331.500+462%
Usd Revenue----0%-0%-0%89451.800-100%
Usd Total Gains Per Share--0.0040.0040%-+100%0.000+15518%-0.015+451%
 EOD+0 -0MRQTTM+0 -0YOY+14 -125Y+14 -1510Y+18 -14

3.2. Fundamental Score

Let's check the fundamental score of Taxus Cardium Pharmaceuticals Group Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.011
Price to Book Ratio (EOD)Between0-1-0.001
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.077
Current Ratio (MRQ)Greater than10.082
Debt to Asset Ratio (MRQ)Less than19.057
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-1.015
Total1/10 (10.0%)

3.3. Technical Score

Let's check the technical score of Taxus Cardium Pharmaceuticals Group Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than500.000
Ma 20Greater thanMa 500.000
Ma 50Greater thanMa 1000.000
Ma 100Greater thanMa 2000.000
OpenGreater thanClose0.000
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2021-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets567
Total Liabilities5,135
Total Stockholder Equity-3,875
 As reported
Total Liabilities 5,135
Total Stockholder Equity+ -3,875
Total Assets = 567

Assets

Total Assets567
Total Current Assets411
Long-term Assets156
Total Current Assets
Cash And Cash Equivalents 386
Other Current Assets 25
Total Current Assets  (as reported)411
Total Current Assets  (calculated)411
+/-0
Long-term Assets
Property Plant Equipment 149
Long-term Assets Other 7
Long-term Assets  (as reported)156
Long-term Assets  (calculated)156
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities5,027
Long-term Liabilities108
Total Stockholder Equity-3,875
Total Current Liabilities
Short-term Debt 1,153
Accounts payable 746
Other Current Liabilities 3,129
Total Current Liabilities  (as reported)5,027
Total Current Liabilities  (calculated)5,027
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)108
Long-term Liabilities  (calculated)0
+/- 108
Total Stockholder Equity
Common Stock4
Retained Earnings -119,430
Other Stockholders Equity 115,551
Total Stockholder Equity (as reported)-3,875
Total Stockholder Equity (calculated)-3,875
+/- 0
Other
Cash and Short Term Investments 386
Common Stock Shares Outstanding 24,116
Liabilities and Stockholders Equity 567
Net Debt 874
Net Working Capital -4,617
Short Long Term Debt Total 1,260



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-311999-12-311998-12-311997-12-311996-12-311995-12-31
> Total Assets 
14,316
22,317
48,273
25,095
0
19,902
4,420
2,707
22,352
14,117
16,926
10,297
5,476
9,512
7,503
7,809
2,786
746
37
37
1,111
162
35
35
567
56735351621,11137377462,7867,8097,5039,5125,47610,29716,92614,11722,3522,7074,42019,902025,09548,27322,31714,316
   > Total Current Assets 
13,063
4,790
26,867
6,910
0
4,218
4,416
2,704
21,958
7,718
9,848
4,042
4,082
8,203
5,374
4,289
492
420
31
31
941
101
33
33
411
411333310194131314204924,2895,3748,2034,0824,0429,8487,71821,9582,7044,4164,21806,91026,8674,79013,063
       Cash And Cash Equivalents 
4,939
4,046
18,186
4,356
0
2,276
4,346
2,686
21,788
5,931
7,723
1,103
3,364
6,644
4,721
2,328
22
217
22
22
930
82
0
0
386
38600829302222217222,3284,7216,6443,3641,1037,7235,93121,7882,6864,3462,27604,35618,1864,0464,939
       Short-term Investments 
0
0
2,097
1,589
0
1,917
0
0
30
0
0
0
563
1,225
150
50
0
0
0
0
0
0
0
0
0
000000000501501,22556300030001,91701,5892,09700
       Net Receivables 
58
212
511
301
0
25
27
0
0
276
566
296
115
0
0
329
0
0
0
0
0
0
0
0
0
00000000032900115296566276002725030151121258
       Inventory 
312
518
751
643
0
86
0
0
0
857
1,037
2,000
0
0
434
1,174
160
0
0
0
0
0
0
0
0
000000001601,174434002,0001,037857000860643751518312
       Other Current Assets 
7,100
-1
5,075
21
0
226
44
18
170
654
522
433
603
1,359
218
457
309
203
9
9
10
19
32
17
25
2517321910992033094572181,35960343352265417018442260215,075-17,100
   > Long-term Assets 
1,252
17,527
21,407
18,185
0
15,684
3
3
394
6,399
7,078
6,255
1,394
1,309
2,130
3,520
2,295
326
7
7
170
61
3
3
156
1563361170773262,2953,5202,1301,3091,3946,2557,0786,3993943315,684018,18521,40717,5271,252
       Property Plant Equipment 
511
14,102
16,676
18,162
0
30
1
1
372
791
1,651
1,706
352
235
136
98
30
16
7
7
158
61
3
3
149
1493361158771630981362353521,7061,6517913721130018,16216,67614,102511
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
585
0
0
0
0
0
0
0
0
0
000000000585000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,700
300
0
0
0
0
0
0
0
00000003001,7000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
5,556
4,766
3,977
0
989
1,333
2,218
0
0
0
0
0
0
0
0
0
0000000002,2181,33398903,9774,7665,556000000000
       Long-term Assets Other 
537
677
156
23
0
15,644
0
0
21
52
661
573
1,042
200
226
185
565
10
7
12
12
0
0
7
7
770012127105651852262001,04257366152210015,644023156677537
> Total Liabilities 
5,673
9,124
13,657
46,692
0
26,579
83
60
614
2,964
8,497
11,052
7,630
2,084
1,418
1,443
1,601
2,428
3,832
3,832
4,400
5,791
4,885
4,885
5,135
5,1354,8854,8855,7914,4003,8323,8322,4281,6011,4431,4182,0847,63011,0528,4972,964614608326,579046,69213,6579,1245,673
   > Total Current Liabilities 
602
4,053
9,083
2,252
0
5,113
83
60
614
2,964
5,255
10,856
7,440
1,346
1,300
1,393
1,601
2,428
3,832
3,832
4,394
5,791
4,763
4,763
5,027
5,0274,7634,7635,7914,3943,8323,8322,4281,6011,3931,3001,3467,44010,8565,2552,96461460835,11302,2529,0834,053602
       Short-term Debt 
27
107
5,025
0
0
0
0
0
0
0
1,482
4,037
0
0
0
0
0
688
946
1,050
1,050
1,066
274
999
1,153
1,1539992741,0661,0501,050946688000004,0371,48200000005,02510727
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
688
946
1,050
1,231
1,066
999
1,084
0
01,0849991,0661,2311,05094668800000000000000000
       Accounts payable 
392
2,025
1,109
519
0
112
53
50
163
989
1,461
4,745
2,301
598
750
778
990
1,204
1,791
1,791
1,673
1,858
4,489
967
746
7469674,4891,8581,6731,7911,7911,2049907787505982,3014,7451,461989163505311205191,1092,025392
       Other Current Liabilities 
183
994
-3,782
1,733
0
5,001
30
10
451
1,975
2,312
2,074
5,139
748
550
615
611
1,224
2,041
2,041
1,670
2,867
0
2,797
3,129
3,1292,79702,8671,6702,0412,0411,2246116155507485,1392,0742,3121,97545110305,00101,733-3,782994183
   > Long-term Liabilities 
5,071
5,071
4,574
44,440
0
21,467
53
50
163
989
3,242
195
190
738
118
50
990
1,204
0
1,791
7
2,924
122
122
108
1081221222,92471,79101,204990501187381901953,242989163505321,467044,4404,5745,0715,071
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
122
122
0
01221220000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
195
191
165
118
50
0
0
0
7
10
0
0
0
0
00001070005011816519119500000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7
0
0
0
0
0
0000070000000000000000000
> Total Stockholder Equity
8,144
13,193
34,472
-21,597
0
-6,677
4,337
2,647
21,738
11,153
8,428
-755
-2,155
7,428
6,085
6,366
1,185
-1,682
-3,794
-3,794
-3,138
-5,157
-4,290
-4,290
-3,875
-3,875-4,290-4,290-5,157-3,138-3,794-3,794-1,6821,1856,3666,0857,428-2,155-7558,42811,15321,7382,6474,337-6,6770-21,59734,47213,1938,144
   Common Stock
344
500
535
8,710
0
9,743
33
33
3
3
4
5
6
8
9
13
13
1
1
1
1
1
1
1
4
411111111313986543333339,74308,710535500344
   Retained Earnings 
-4,068
-12,389
-28,454
-55,867
0
-66,783
2,503
2,157
-5,446
-24,039
-49,361
-73,959
-76,226
-80,962
-88,091
-96,414
-105,329
-110,834
-114,532
-115,159
-117,450
-119,779
-118,912
-118,912
-119,430
-119,430-118,912-118,912-119,779-117,450-115,159-114,532-110,834-105,329-96,414-88,091-80,962-76,226-73,959-49,361-24,039-5,4462,1572,503-66,7830-55,867-28,454-12,389-4,068
   Accumulated Other Comprehensive Income 
7
-654
-3,329
-3,713
0
-3,150
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
600
0
060000000000000000000-3,1500-3,713-3,329-6547
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
106,501
0
110,764
113,711
0
0
114,021
114,021
0
0114,021114,02100113,711110,7640106,5010000000000000000
   Treasury Stock0000000000000000000000000
   Other Stockholders Equity 
11,860
25,735
65,579
29,272
0
53,512
1,801
457
27,181
35,189
57,785
73,199
74,066
88,382
94,167
102,767
106,501
109,151
600
111,364
114,311
114,621
600
114,021
115,551
115,551114,021600114,621114,311111,364600109,151106,501102,76794,16788,38274,06673,19957,78535,18927,1814571,80153,512029,27265,57925,73511,860



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.